Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Harvard Business School
Farmers Insurance
Fuji
Healthtrust

Generated: May 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,473,761

« Back to Dashboard

Summary for Patent: 7,473,761
Title:Somatostatin analogues
Abstract: The invention provides cyclo[{4-(NH.sub.2--C.sub.2H.sub.4--NH--CO--O--)Pro}-Phg-DTrp-Lys-Tyr(4-B- enzyl)-Phe], optionally in protected form, or a pharmaceutically acceptable salt or complex thereof, which has interesting pharmaceutical properties.
Inventor(s): Albert; Rainer (Basel, CH), Bauer; Wilfried (Lampenberg, CH), Bodmer; David (Klingnau, CH), Bruns; Christian (Freiburg, DE), Felner; Ivo (Reinach, CH), Hellstern; Heribert (Heitersheim, DE), Lewis; Ian (Riehen, CH), Meisenbach; Mark (Durmenach, FR), Weckbecker; Gisbert (Biel-Benken, CH), Wietfeld; Bernhard (Efringen-Kirchen, DE)
Assignee: Novartis AG (Basel, CH)
Application Number:10/343,288
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,473,761
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,473,761

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Novartis Pharms Corp SIGNIFOR LAR KIT pasireotide pamoate FOR SUSPENSION;INTRAMUSCULAR 203255-001 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR KIT pasireotide pamoate FOR SUSPENSION;INTRAMUSCULAR 203255-002 Dec 15, 2014 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis Pharms Corp SIGNIFOR LAR KIT pasireotide pamoate FOR SUSPENSION;INTRAMUSCULAR 203255-003 Dec 15, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis SIGNIFOR pasireotide diaspartate SOLUTION;SUBCUTANEOUS 200677-001 Dec 14, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis SIGNIFOR pasireotide diaspartate SOLUTION;SUBCUTANEOUS 200677-002 Dec 14, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Novartis SIGNIFOR pasireotide diaspartate SOLUTION;SUBCUTANEOUS 200677-003 Dec 14, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,473,761

PCT Information
PCT FiledJuly 30, 2001PCT Application Number:PCT/EP01/08824
PCT Publication Date:February 07, 2002PCT Publication Number: WO02/10192

International Family Members for US Patent 7,473,761

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 034132 ➤ Try a Free Trial
Austria 393782 ➤ Try a Free Trial
Australia 2001289778 ➤ Try a Free Trial
Australia 8977801 ➤ Try a Free Trial
Brazil 0112859 ➤ Try a Free Trial
Brazil PI0112859 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Accenture
Cipla
Moodys
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.